Fig. 8

Poly (ε-caprolactone)-based intracameral drug delivery systems. A Schematic representation of the synthesis of pilocarpine-loaded PCL nanospheres (NSs) (a) and PCL nanocapsules (NCs) (b) via the emulsion-solvent evaporation method. B Scanning electron microscopic images of (c) pilocarpine-loaded NSs (PILO-PCL NSs) and (d) pilocarpine-loaded NCs (PILO-PCL NCs) dispersed in BSS buffer (i) and at day 42 (ii) and day 70 (iii). C IOP change of glaucomatous rabbit eyes treated with 20 μL of PILO-PCL NSs or PILO-PCL NCs. Follow-up time point: day (d). D Representative photograph after device implantation. E IOP changes of the eyes after DE-117-loaded device implantation. E Concentration of DE-117 and hDE-117 (active form of DE-117) in the aqueous humor and vitreous (e, f) and iris-ciliary body (g, h) at different time points after the administration of DE-117-loaded implant. A—C Reproduced from Ref. [160] with permission from the Royal Society of Chemistry. (D)—(F): Reprinted from Ref. [123] with permission from Elsevier